Walter V. Klemp, CEO and President of Moleculin Biotech, Inc. (NASDAQ:MBRX), filed a Form 4 on November 18, 2026, disclosing transactions dated November 16, 2026, involving the vesting of restricted stock units and a share withholding for tax obligations.
Key Highlights
- RSU conversion: 577 restricted stock units were converted into 577 shares of common stock on November 16, 2026, via transaction code M.
- Tax withholding: 141 shares were withheld at $7.41 per share on November 16, 2026, to cover tax obligations upon vesting.
- Post-transaction common stock holdings: Klemp directly owns 36,545 shares of common stock following the reported transactions.
- Remaining RSU balance: Klemp holds 126,838 restricted stock units following the transaction.
- Vesting schedule: The RSU award vests 50% on grant and 50% in 18 equal installments over 18 months, according to the filing.
- Roles: The filing identifies Klemp as both a Director and the CEO and President of Moleculin Biotech, Inc.
Klemp RSU Vesting and Tax Withholding Details at Moleculin Biotech
According to the Form 4 filed on November 18, 2026, Walter V. Klemp, CEO, President, and Director of Moleculin Biotech, Inc. (NASDAQ:MBRX), reported two transactions in the company's common stock on November 16, 2026. The first was an acquisition of 577 shares (transaction code M), reflecting the conversion of an equal number of restricted stock units into common stock on a one-for-one basis. The second was a disposition of 141 shares (transaction code F) at a price of $7.41 per share, representing shares withheld for the payment of taxes upon the vesting of restricted stock unit awards.
As a result of these transactions, the filing reports that Klemp directly holds 36,545 shares of Moleculin Biotech common stock. In Table II, the filing shows that 577 restricted stock units were disposed of via the M code conversion, leaving Klemp with a remaining balance of 126,838 restricted stock units, all held directly. The filing notes that each restricted stock unit represents a contingent right to receive one share of company common stock, and that the derivative security carries a price of $0.
The filing describes the vesting terms of the RSU award as follows: 50% vests on grant, and the remaining 50% vests in 18 equal installments over 18 months. The Form 4 was signed by Jonathan P. Foster by Power of Attorney on November 18, 2026. No 10b5-1 plan checkbox was indicated as checked in this filing.
What Was Disclosed
Moleculin Biotech's CEO and President Walter V. Klemp disclosed the vesting of 577 restricted stock units into common stock and the withholding of 141 shares at $7.41 for tax purposes on November 16, 2026, leaving him with 36,545 shares of common stock and 126,838 RSUs outstanding.




Please wait processing your request...